FZD6抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P04518(FZD6 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04518(FZD6 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

**Background of FZD6 Antibody**

The FZD6 antibody is a tool designed to detect Frizzled-6 (FZD6), a member of the Frizzled family of G protein-coupled receptors that serve as key receptors in the Wnt signaling pathway. FZD6 specifically interacts with Wnt ligands to regulate both canonical (β-catenin-dependent) and non-canonical (e.g., planar cell polarity, Wnt/Ca²⁺) signaling pathways. These pathways are critical in embryonic development, tissue homeostasis, and cell polarity regulation. Dysregulation of FZD6 has been implicated in various cancers, including breast cancer, leukemia, and glioblastoma, where it may promote tumor progression, metastasis, or therapy resistance.

FZD6 antibodies are widely used in research to study the receptor’s expression, localization, and function in cellular and tissue contexts. They enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels or track dynamic changes during disease states. Some antibodies target specific epitopes or post-translational modifications, aiding in mechanistic studies. Commercial FZD6 antibodies are often validated for specificity using knockout cell lines or siRNA-mediated silencing.

Research on FZD6 also explores its therapeutic potential, as targeting FZD6 or its downstream effectors may offer novel strategies for cancer treatment or regenerative medicine. However, challenges remain in understanding its context-dependent roles and interactions with co-receptors like LRP5/6. The FZD6 antibody thus serves as a vital reagent for unraveling the complexities of Wnt signaling in health and disease.